Event snippet :
top of page
ABR-Biosynth logo.png

ABOUT US

​​

  • One of the longest, established, privately held biotech companies, founded in 1978.

​

  • Leading global provider of high-quality raw materials to the in-vitro diagnostic industry and research laboratories.

​

  • ISO 13485:2016 registered.
     

  • Joined the Biosynth Group to form the biologics division in May 2022.
     

  • Rebranded to Biosynth Ltd. on 1st August 2023.

KEY CAPABILITIES

​​

  • First to market proteins and monoclonal antibodies for the new emerging viruses, eg. Dengue, Chikungunya and Zika, Sars, Covid -19 and VEEV virus.

​

  • Wide range of well-established products for chemiluminscence, ELISA, lateral flow and other immunoassay formats.
     

  • Custom manufacture of antibodies and recombinant antigens under ISO 13485:2016 conditions

OUR GOAL

​​

  • To maintain our position as the leading global provider of high-quality and esoteric biological raw materials to the in-vitro diagnostic industry.

​

  • To enable our customers to bring ground-breaking technology to the market faster allowing cost-effective and efficient patient management at the point of impact.

bottom of page